FI963510A0 - Isoksatsoliiniyhdisteitä TNF:n vapautumisen inhibiittoreina - Google Patents

Isoksatsoliiniyhdisteitä TNF:n vapautumisen inhibiittoreina

Info

Publication number
FI963510A0
FI963510A0 FI963510A FI963510A FI963510A0 FI 963510 A0 FI963510 A0 FI 963510A0 FI 963510 A FI963510 A FI 963510A FI 963510 A FI963510 A FI 963510A FI 963510 A0 FI963510 A0 FI 963510A0
Authority
FI
Finland
Prior art keywords
disease
inhibitors
isoxazoline compounds
compounds
tnf
Prior art date
Application number
FI963510A
Other languages
English (en)
Finnish (fi)
Swedish (sv)
Other versions
FI963510A (fi
Inventor
Victoria L Cohan
Edward F Kleinman
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of FI963510A publication Critical patent/FI963510A/fi
Publication of FI963510A0 publication Critical patent/FI963510A0/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/04—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • AIDS & HIV (AREA)
  • Nutrition Science (AREA)
  • Obesity (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Hydrogenated Pyridines (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
FI963510A 1994-03-09 1996-09-06 Isoksatsoliiniyhdisteitä TNF:n vapautumisen inhibiittoreina FI963510A0 (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US20912594A 1994-03-09 1994-03-09
PCT/IB1995/000078 WO1995024398A1 (en) 1994-03-09 1995-02-03 Isoxazoline compounds as inhibitors of tnf release

Publications (2)

Publication Number Publication Date
FI963510A FI963510A (fi) 1996-09-06
FI963510A0 true FI963510A0 (fi) 1996-09-06

Family

ID=22777444

Family Applications (1)

Application Number Title Priority Date Filing Date
FI963510A FI963510A0 (fi) 1994-03-09 1996-09-06 Isoksatsoliiniyhdisteitä TNF:n vapautumisen inhibiittoreina

Country Status (18)

Country Link
US (2) US5869511A (xx)
EP (1) EP0749428B1 (xx)
JP (1) JPH09505082A (xx)
KR (1) KR100200449B1 (xx)
CN (1) CN1143363A (xx)
AT (1) ATE169009T1 (xx)
AU (1) AU684887B2 (xx)
CA (1) CA2185019C (xx)
DE (1) DE69503769T2 (xx)
DK (1) DK0749428T3 (xx)
ES (1) ES2118557T3 (xx)
FI (1) FI963510A0 (xx)
IL (1) IL112847A (xx)
MY (1) MY114667A (xx)
NO (1) NO310496B1 (xx)
NZ (1) NZ278667A (xx)
WO (1) WO1995024398A1 (xx)
ZA (1) ZA951909B (xx)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6022977A (en) 1997-03-26 2000-02-08 Dupont Pharmaceuticals Company Dynamic resolution of isoxazoline thioesters to isoxazoline carboxylic acids
WO1999005130A1 (de) * 1997-07-23 1999-02-04 Basf Aktiengesellschaft Substituierte 3-phenylisoxazoline
WO1999014210A1 (en) * 1997-09-15 1999-03-25 Warner-Lambert Company Process for the preparation of substituted 5,6-dihydro-2h-pyran-2-ones
EP1102755B1 (en) 1998-08-07 2006-01-04 Chiron Corporation Substituted isoxazole derivatives as estrogen receptor modulators
ATE259803T1 (de) * 1998-10-09 2004-03-15 Janssen Pharmaceutica Nv 4,5-dehydroisoxazole derivate und ihre pharmazeutische verwendung
US20040220103A1 (en) * 1999-04-19 2004-11-04 Immunex Corporation Soluble tumor necrosis factor receptor treatment of medical disorders
US20020077276A1 (en) * 1999-04-27 2002-06-20 Fredeking Terry M. Compositions and methods for treating hemorrhagic virus infections and other disorders
KR100399361B1 (ko) * 1999-11-04 2003-09-26 주식회사 엘지생명과학 캐스파제 억제제 함유 치료제 조성물
EP1212309B1 (en) * 1999-09-17 2004-08-18 LG Chem Investment, Ltd. Caspase inhibitor
US6808902B1 (en) 1999-11-12 2004-10-26 Amgen Inc. Process for correction of a disulfide misfold in IL-1Ra Fc fusion molecules
GB0021776D0 (en) * 2000-09-05 2000-10-18 Arakis Ltd The treatment of inflammatory disorders
EP1411930B1 (en) 2001-06-08 2013-01-16 Cytokine Pharmasciences, Inc. Isoxazoline compounds having mif antagonist activity
ATE464068T1 (de) 2001-06-26 2010-04-15 Amgen Fremont Inc Antikörper gegen opgl
AU2002316384A1 (en) * 2001-06-26 2003-03-03 Photomed Technologies, Inc. Multiple wavelength illuminator
AU2003301903A1 (en) * 2002-11-06 2004-06-03 Bristol-Myers Squibb Company Isoxazoline derivatives as inhibitors of matrix metalloproteinases and/or tnf-alpha converting enzyme
EP1578782A4 (en) * 2002-12-30 2007-09-12 Amgen Inc COSTIMULATING FACTORIAL THERAPY
NZ545748A (en) 2003-08-29 2010-03-26 Ranbaxy Lab Ltd Isoxazoline derivatives as inhibitors of phosphodiesterase type-IV
WO2005051931A2 (en) * 2003-11-26 2005-06-09 Ranbaxy Laboratories Limited Phosphodiesterase inhibitors
EA014881B1 (ru) 2004-03-05 2011-02-28 Ниссан Кемикал Индастриз, Лтд. Производные замещенного алкилбензола
BRPI0507818A (pt) * 2004-03-26 2007-07-10 Cytokine Pharmasciences Inc composto e métodos de inibição
RU2416606C2 (ru) 2004-06-17 2011-04-20 Инфинити Дискавери, Инк. Соединения и способы для ингибирования взаимодействия bcl белков с компонентами по связыванию
US7842815B2 (en) 2004-06-17 2010-11-30 Infinity Pharmaceuticals, Inc. Compounds and methods for inhibiting the interaction of BCL proteins with binding partners
US20080009535A1 (en) * 2004-08-30 2008-01-10 Sarala Balachandran Inhibitors of phosphodiesterase type-IV
JP5336175B2 (ja) * 2005-03-15 2013-11-06 ガニアル・イミュノセラピューティクス・インコーポレーテッド 免疫調整剤活性を有する化合物
DE602007006288D1 (de) 2006-03-10 2010-06-17 Nissan Chemical Ind Ltd Substituierte isoxazolin-verbindung und schädlingsbekämpfungsmittel
US7932052B1 (en) * 2006-07-24 2011-04-26 The Regents Of The University Of Michigan Use of methanobactin
TWI389895B (zh) 2006-08-21 2013-03-21 Infinity Discovery Inc 抑制ｂｃｌ蛋白質與結合夥伴間之交互作用的化合物及方法
US20100029728A1 (en) * 2006-09-22 2010-02-04 Ranbaxy Laboratories Limited Phosphodiesterase inhibitors
CA2686766A1 (en) * 2007-05-09 2008-11-20 Ganial Immunoterapeutics Inc. (s,r)-3-phenyl-4,5 dihydro-5-isoxazole acetic acid-nitric oxide and use thereof as anti-cancer and antiviral agent
EA201171035A1 (ru) * 2009-02-10 2012-02-28 Селджин Корпорейшн Композиции, включающие модуляторы pde4, и способ их применения для лечения, профилактики и сопровождения туберкулеза
US20150064221A1 (en) 2012-04-17 2015-03-05 Niranjan Y. Sardesai Compounds having immunomudulator activity
CN102911131B (zh) * 2012-10-24 2014-10-29 中化蓝天集团有限公司 一种双键桥三氟甲基异噁唑类化合物、其制备方法及应用
CN105814022B (zh) * 2013-12-09 2018-09-28 Ucb生物制药私人有限公司 作为tnf活性调节剂的稠合的二环杂芳族衍生物

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3995048A (en) * 1975-10-20 1976-11-30 Sandoz, Inc. Isoxazolyl benzamides useful as tranquilizers and sleep-inducers
US4112108A (en) * 1976-12-06 1978-09-05 Sandoz, Inc. Isoxazolyl benzamides
JPS5512038A (en) * 1978-07-07 1980-01-28 Ube Industries Packing sack made of flat thread made from resin film
JPS55104273A (en) * 1979-02-05 1980-08-09 Sankyo Co Ltd 4-phenylisoxazole derivative and its preparation
CA1128526A (en) * 1979-10-05 1982-07-27 Cdc Life Sciences Inc. 3,4-diarylisoxazol-5-acetic acids
HU215433B (hu) * 1986-04-29 2000-05-28 Pfizer Inc. Eljárás új 2-oxo-5-fenil-pirimidin-származékok előállítására
US4892870A (en) * 1988-08-01 1990-01-09 Biofor, Ltd. Oxaza heterocycles and pharmaceutical compositions containing same
FR2639636B1 (fr) * 1988-11-30 1994-03-04 Novapharme Nouveaux composes heterocycliques a activite anticonvulsivante, procede de preparation et compositions therapeutiques les contenant
DE3914969A1 (de) * 1989-05-02 1990-11-08 Schering Ag 5-substituierte 3-arylisoxazol-derivate, deren herstellung und verwendung als schaedlingsbekaempfungsmittel
CA2017383A1 (en) * 1989-06-08 1990-12-08 Raymond R. Martodam Use of vanilloids for the treatment of respiratory diseases or disorders
JPH05503919A (ja) * 1989-06-13 1993-06-24 スミスクライン・ビーチャム・コーポレイション 単球および／またはマクロファージによるインターロイキン―１または腫瘍壊死因子生成の抑制
WO1991007177A1 (en) * 1989-11-13 1991-05-30 Pfizer Inc. Pyrimidone derivatives and analogs in the treatment of asthma or certain skin disorders
GB9007762D0 (en) * 1990-04-05 1990-06-06 Beecham Group Plc Novel compounds
US5051438A (en) * 1990-05-16 1991-09-24 G. D. Searle & Co. Alkoxy-substituted dihydrobenzopyran-2-carboxylic acids and derivatives thereof, compositions and use
DE4016049A1 (de) * 1990-05-18 1991-11-21 Basf Ag 3-isoxazolylbenzylester, ihre herstellung und ihre verwendung
KR930703262A (ko) * 1990-11-06 1993-11-29 스튜어트 알. 슈터 이미다졸리디논 화합물
PT100441A (pt) * 1991-05-02 1993-09-30 Smithkline Beecham Corp Pirrolidinonas, seu processo de preparacao, composicoes farmaceuticas que as contem e uso
JP2702833B2 (ja) * 1991-10-09 1998-01-26 松下電器産業株式会社 レーザ加工装置
US5716967A (en) * 1993-11-26 1998-02-10 Pfizer Inc. Isoxazoline compounds as antiinflammatory agents

Also Published As

Publication number Publication date
CN1143363A (zh) 1997-02-19
EP0749428B1 (en) 1998-07-29
MX9603975A (es) 1997-09-30
IL112847A0 (en) 1995-06-29
FI963510A (fi) 1996-09-06
DK0749428T3 (da) 1998-11-16
AU684887B2 (en) 1998-01-08
US5869511A (en) 1999-02-09
DE69503769D1 (de) 1998-09-03
ZA951909B (en) 1996-09-09
CA2185019C (en) 2000-08-08
WO1995024398A1 (en) 1995-09-14
JPH09505082A (ja) 1997-05-20
KR100200449B1 (ko) 1999-06-15
AU1464795A (en) 1995-09-25
ES2118557T3 (es) 1998-09-16
MY114667A (en) 2002-12-31
IL112847A (en) 1999-10-28
NO963746L (no) 1996-11-06
ATE169009T1 (de) 1998-08-15
NZ278667A (en) 2000-12-22
DE69503769T2 (de) 1998-12-03
NO310496B1 (no) 2001-07-16
US6114367A (en) 2000-09-05
NO963746D0 (no) 1996-09-06
EP0749428A1 (en) 1996-12-27

Similar Documents

Publication Publication Date Title
NO963746L (no) Isoksalin-forbindelser som inhibitorer for frigivning av TNF
MX9504020A (es) Compuestos de catecol dieter como inhibidores de la liberacion de factor de necrosis tumoral.
FI945556A0 (fi) Tulehdustenvastaiset 3-aryyli-2-isoksatsoliinijohdannaiset
DK0730579T3 (da) Substituerede indoler som inhibitorer af phosphodiesterase-type-IV
ES2104424T3 (es) Compuestos de isoxazolina como agentes antiinflamatorios.
DK1045690T3 (da) Benzensulfonamidinhibitorer af PDE-IV og deres terapeutiske anvendelse
RU95113454A (ru) Катехольные диэфиры как селективные ингибиторы фдэiv, фармацевтическая композиция, способы лечения
WO2005019190A3 (en) (4 -amino -1,2, 5-oxadiazol-4-yl) -hetξroaromatic compounds useful as protein kinase inhibitors
NO982185L (no) Nye makrosykliske forbindelser som metalloproteinaseinhibitorer
NO971811L (no) Bicykliske tetrahydropyrazolopyridiner og deres anvendelse som legemidler
WO2008071605A3 (en) Methods of treating inflammatory diseases
DE69811360T2 (de) Diazepinoindolone als phophodiesterase 4 inhibitoren
DK0752990T3 (da) Benzisothiazolderivater som inhibitorer af 5-lipoxygenasebiosyntese
MX9603943A (es) Compuestos de isoxazolina como inhibidores de 5-lipooxigenasa.
CL2008002853A1 (es) Compuestos derivados de piraziin quinolina sustituida, inhibidores de la migracion de macrofagos (mif); y su uso en el tratamiento de inflamacion, shock septico, artritis, cancer, trastornos autoinmunes e inhibicion de angiogenesis (divisional de la solicitud 1088-02)

Legal Events

Date Code Title Description
MA Patent expired